Advertisement

Topics

Companies Related to "18F-FCH PET/MRI to Assess Tumor Response in Castration Resistant Prostate Cancer" [Most Relevant Company Matches] RSS

01:04 EDT 24th October 2018 | BioPortfolio

Here are the most relevant search results for "18F-FCH PET/MRI to Assess Tumor Response in Castration Resistant Prostate Cancer" found in our extensive corporate database of over 50,000 company records.

Showing "Assess Tumor Response Castration Resistant Prostate Cancer" Companies 1–25 of 3,100+

Extremely Relevant

Glactone Pharma AB

Glactone Pharma AB is developing a drug for the treatment of castration resistant prostate cancer. Research has shown that the natural product galiellalactone can modulate a signaling protein (STAT3) that is over activated in cancer cells. The goal is to develop drugs against metastasizing cancer where galiellalactone is used as a chemical starting point to make new novel, patentable compounds. ...


Tokai Pharmaceuticals

Tokai Pharmaceuticals is a U.S. biopharmaceutical company focused on developing new treatments for prostate cancer. The company’s lead drug candidate, TOK-001, is the first investigational new drug that can decrease overall androgen receptor levels in prostate tumors and in which three distinct mechanisms of action are combined in one oncotherapeutic....

Aragon Pharmaceuticals Inc.

Aragon Pharmaceuticals is a privately held small-molecule drug discovery company identifying breakthrough medicines for the treatment of hormonally driven cancers. These cancers are traditionally treated with anti-hormonal therapies but often become resistant, and follow-on therapies are largely ineffective. The company plans to initiate a clinical trial with its lead compound, ARN-509, in patient...


Tokai Pharmaceuticals, Inc.,

Tokai Pharmaceuticals is a biopharmaceutical company focused on developing new treatments for prostate cancer and other hormonally driven cancers. The company’s lead drug candidate, galeterone (TOK-001), is a first-in-class, multi-targeted, oral small molecule drug being developed for the treatment of patients with castration-resistant prostate cancer...

Tokai Pharmaceuticals Inc.

Tokai Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases. The company’s lead drug candidate, galeterone, is a highly selective, multi-targeted oral small molecule being developed for the treatment of patients with metastatic castratio...

Innocrin Pharmaceuticals, Inc.

Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer. VT-464 and the entire CYP17 inhibitor patent estate are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as we...

Prostate Cancer Education Council

Prostate cancer remains the second-leading cause of cancer death in American men. More than 220,000 men will be diagnosed with prostate cancer this year and it is expected that 27,000 men will die from the disease. With more annual cases of prostate cancer than that of breast cancer among women, screening is imperative to ensure the health of the men of our nation.

Prostate Cancer Foundation

The Prostate Cancer Foundation (PCF) is the world’s largest philanthropic source of support for accelerating the world’s most promising research for discovering better treatments and cures for prostate cancer. Founded in 1993, the PCF has raised nearly $400 million and provided funding to more than 1,500 researchers at nearly 200 institutions wor...

The Prostate Cancer Foundation

The Prostate Cancer Foundation is the world’s largest philanthropic source of support for prostate cancer research focused on discovering better treatments and a cure for prostate cancer at every stage of diagnosis. Founded in 1993, the PCF has raised more than $370 million and provided funding to more than 1,500 research projects at nearly 200 instit...

Medivation, Inc.

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer, Inc to develop an...

Relevant

Stratify Genomics, Inc.

Currently, there are 35,000 men annually who are unaware of a curable form of clinically significant prostate cancer. Relying solely on family history, 80% of prostate cancer cases would be missed. The most common screening tool, prostate-specific antigen (PSA) testing, has declined in usage due to controversial guidelines, which has led to a significant i...

Prostate Oncology Specialists, Inc.

According to the American Cancer Society, prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than two million men in the United States have prostate cancer, with an estimated 217,730 new cases and approximately 32,050 men expected to die from the disease in 2010.

Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals, Inc. is developing next generation therapeutic vaccines for the treatment of cancer and infectious diseases. The company's pharmacologically regulated DeCIDe(TM) vaccines are designed to kill targeted cells by inducing a potent, durable, fully activated antigen-specific TH1 immune response. Lead product BPX-101, an autologous DeCIDe(TM) vaccine, is in clinical development...

Asana BioSciences, LLC

Asana BioSciences, LLC, an independent member of the Amneal Alliance of Companies, is a research and development company based in Bridgewater, NJ specializing in the discovery and development of new chemical and biological entities. Asana’s portfolio consists of multiple early-stage drug discovery and development candidates in a variety of therapeutic ...

Dendreon Corporation

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates de...

RC Cancer Centers

Each year thousands of patients from around the world and across the United States turn to RC Cancer Centers seeking a cure for their prostate cancer and learn why they are The Choice for Saving Lives. Founded in 1979, Radiotherapy Centers of Georgia, a division of RC Cancer Centers, has earned a reputation for being one of the country's top cancer treatment and research facilities because of its ...

Prostate Oncology Specialists,Inc.

Prostate Oncology Specialists is a medical group exclusively devoted to caring for men with prostate cancer. We have vast experience diagnosing and treating prostate cancer because 100% of our time is focused on managing men with this disease. Our physicians are board certified in both medical oncology and internal medicine and have made significant contributions to the scientific advancement in t...

Theragenics

Theragenics Corporation is a leader in the production and sales of implantable radiation devices ("seeds") used in thetreatment of cancer. The Company produces and sells TheraSeed(R), which is a U.S. Food and Drug Administration (FDA) licensed device, based on the radioactive isotope palladium 103 (Pd-103). The Company received FDA clearanceto market TheraSeed(R) in 1986 and...

Minomic International Ltd

Minomic International Ltd is an Australian immuno-oncology company specialising in therapeutics and diagnostics for prostate cancer and other cancers. Minomic has developed the in vitro diagnostic test called MiCheck® for the early detection of prostate cancer. Minomic is preparing to globally launch its first product, a novel prostate cancer blood test...

Quentis Therapeutics Inc.

Quentis Therapeutics is a preclinical stage biotechnology company that is pursuing first-in-class endoplasmic reticulum (ER) stress response-targeted therapies to address serious diseases such as cancer. Based on our deep expertise in ER stress biology and the tumor microenvironment, we are pioneering the use of ER stress response modulators to boost the i...

Genetronics Biomedical

Genetronics' most advanced effort involves treating those with head and neck cancer, a particularly devastating cancer that can severely limit the ability of these patients to see, taste, hear, talk, breathe, or swallow. Genetronics received approval from the U.S. Food and Drug Administration and initiated Phase II multi-center clinical trials at nine sites in the U.S. The trials test the effectiv...

BSD Medical

BSD Medical Corporation (AMEX: BSM) develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radio frequency (RF) and microwave energy. BSD Medical is also making major progress in the application of its technology for other therapies. Microwave and RF hyperthermia therapy has been shown to substantially improve local con...

Northwest Biotherapeutics

Northwest Biotherapeutics (NWBT) is a biotechnology company focused on the clinical development of autologous immunotherapy products for cancer. Our technology platform, DCVax®, uses a patient’s own dendritic cells, the starter engine of the immune system, which are loaded with tumor proteins or antigens. Injection of these cells back into the patient initiates a potent immune response against ...

OncoRx Pharmaceuticals Inc.

OncoRx Pharmaceuticals (www.oncorxpharmaceuticals.com) is an early-stage pharmaceutical company dedicated to the discovery and development of novel drugs that control tumor metastasis; disrupt proliferation; and downregulate tissue invasion of drug-resistant tumor cells. In the near term, the Company is planning clinical development programs for the treatm...

Checkmate Pharmaceuticals, Inc.

Checkmate Pharmaceuticals is a research and development company pursuing a novel approach to specifically activating the innate arm of the immune system to recognize and ultimately destroy tumor cells. The company is leveraging their expertise and the vast body of knowledge in the field of CpG oligonucleotides and is validating an approach that will combine ...


More From BioPortfolio on "18F-FCH PET/MRI to Assess Tumor Response in Castration Resistant Prostate Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks